The association between the Survivin A9194G exon polymorphisms and papillary thyroid carcinoma risk in the Han Chinese population

Pathology Research and Practice

Volumn 209, Issue 3, 2013, Pages 151-154

  Wang, Ying Xue ^a,b   Li, Ming Long ^a   Yu, Su Guo ^b   Liu, Chang Mei ^b   Han, Yong ^b   Wang, Xiu Yun ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Papillary thyroid carcinoma; Polymorphism; Survivin

Indexed keywords

ADENOSINE; GUANIDINE; SURVIVIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RISK; CHINESE; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; POPULATION RESEARCH; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVIN GENE; THYROID CARCINOMA;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CASE-CONTROL STUDIES; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; THYROID NEOPLASMS;

EID: 84875377202     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.01.004     Document Type: Article

References (42)

1. DeGroot L.J., Kaplan E.L., McCormick M., Straus F.H. Natural history, treatment, and course of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1990, 71:414-424.
2. Sebastian S.O., Gonzalez J.M., Paricio P.P., et al. Papillary thyroid carcinoma: prognostic index for survival including the histological variety. Arch. Surg. 2000, 135:272-277.
3. Nikiforov Y.E. Is ionizing radiation responsible for the increasing incidence of thyroid cancer?. Cancer 2010, 116:1626-1628.
4. Hegedus L. Clinical practice. The thyroid nodule. N. Engl. J. Med. 2004, 351:1764-1771.
5. How J., Tabah R. Explaining the increasing incidence of differentiated thyroid cancer. CMAJ 2007, 177:1383-1384.
6. Shore R.E. Issues and epidemiological evidence regarding radiation-induced thyroid cancer. Radiat. Res. 1992, 131:98-111.
7. Paschke R., Schmid K.W., Gartner R., Mann K., Dralle H., Reiners C. Epidemiology, pathophysiology, guideline-adjusted diagnostics, and treatment of thyroid nodules. Med. Klin. (Munich) 2010, 105:80-87.
8. Dean D.S., Gharib H. Epidemiology of thyroid nodules. Best Pract. Res. Clin. Endocrinol. Metab. 2008, 22:901-911.
9. Hu J.J., Mohrenweiser H.W., Bell D.A., Leadon S.A., Miller M.S. Symposium overview: genetic polymorphisms in DNA repair and cancer risk. Toxicol. Appl. Pharmacol. 2002, 185:64-73.
10. Li F., Ling X. Survivin study: an update of " what is the next wave" ?. J. Cell. Physiol. 2006, 208:476-486.
11. Salvesen G.S., Duckett C.S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 2002, 3:401-410.
12. Schimmer A.D. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 2004, 64:7183-7190.
13. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3:917-921.
14. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22:8581-8589.
15. Li F., Ambrosini G., Chu E.Y., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
16. Vandghanooni S., Eskandani M., Montazeri V., Halimi M., Babaei E., Feizi M.A. Survivin-deltaEx3: a novel biomarker for diagnosis of papillary thyroid carcinoma. J. Cancer Res. Ther. 2011, 7:325-330.
17. Antonaci A., Consorti F., Mardente S., Natalizi S., Giovannone G., Della Rocca C. Survivin and cyclin D1 are jointly expressed in thyroid papillary carcinoma and microcarcinoma. Oncol. Rep. 2008, 20:63-67.
18. Kawata N., Tsuchiya N., Horikawa Y., et al. Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int. J. Cancer 2011, 129:1872-1880.
19. Xu Y., Fang F., Ludewig G., Jones G., Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004, 23:419-429.
20. Jang J.S., Kim K.M., Kang K.H., et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 2008, 60:31-39.
21. Gazouli M., Tzanakis N., Rallis G., et al. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int. J. Colorectal Dis. 2009, 24:145-150.
22. Yang X., Xiong G., Chen X., et al. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2009, 135:1341-1349.
23. Edge S.B., American Joint Committee on Cancer AJCC Cancer Staging Manual 2010, Springer, New York.
24. Thatte U., Dahanukar S. Apoptosis: clinical relevance and pharmacological manipulation. Drugs 1997, 54:511-532.
25. Duffy M.J., O'Donovan N., Brennan D.J., Gallagher W.M., Ryan B.M. Survivin: a promising tumor biomarker. Cancer Lett. 2007, 249:49-60.
26. Melet A., Song K., Bucur O., Jagani Z., Grassian A.R., Khosravi-Far R. Apoptotic pathways in tumor progression and therapy. Adv. Exp. Med. Biol. 2008, 615:47-79.
27. Mathew R., White E. FLIPping the balance between apoptosis and proliferation in thyroid cancer. Clin. Cancer Res. 2006, 12:3648-3651.
28. Fukuda S., Pelus L.M. Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther. 2006, 5:1087-1098.
29. Altieri D.C. Validating survivin as a cancer therapeutic target. Nature reviews. Cancer 2003, 3:46-54.
30. Reed J.C. The Survivin saga goes in vivo. J. Clin. Invest. 2001, 108:965-969.
31. Tamm I., Wang Y., Sausville E., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998, 58:5315-5320.
32. Shin S., Sung B.J., Cho Y.S., et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001, 40:1117-1123.
33. Sun C., Nettesheim D., Liu Z., Olejniczak E.T. Solution structure of human survivin and its binding interface with Smac/Diablo. Biochemistry 2005, 44:11-17.
34. Liu T., Brouha B., Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 2004, 23:39-48.
35. Wang Y.H., Chiou H.Y., Lin C.T., et al. Association between survivin gene promoter -31C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology 2009, 73:670-674.
36. Borbely A.A., Murvai M., Szarka K., et al. Survivin promoter polymorphism and cervical carcinogenesis. J. Clin. Pathol. 2007, 60:303-306.
37. Borges Bdo N., Burbano R.R., Harada M.L. Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin. Exp. Med. 2011, 11:189-193.
38. Theodoropoulos G.E., Michalopoulos N.V., Panoussopoulos S.G., Taka S., Gazouli M. Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas 2010, 39:976-980.
39. Upadhyay R., Khurana R., Kumar S., Ghoshal U.C., Mittal B. Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann. Surg. Oncol. 2011, 18:880-887.
40. Xu Y., Fang F., Ludewig G., Jones G., Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004, 23:527-537.
41. Wagner M., Schmelz K., Dorken B., Tamm I. Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk. Res. 2008, 32:1054-1060.
42. Yazdani N., Sayahpour F.A., Haghpanah V., et al. Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol. Res. Pract. 2012, 208:100-103.